Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial
about
Thrombolysis for acute ischaemic strokeImproving the reliability of stroke disability grading in clinical trials and clinical practice: the Rankin Focused Assessment (RFA).Mechanical thrombectomy for emergent large vessel occlusion: a critical appraisal of recent randomized controlled clinical trialsIntravenous Thrombolysis for Acute Ischemic Stroke Within 3 Hours Versus Between 3 and 4.5 Hours of Symptom OnsetInteraction of ARC and Daxx: A Novel Endogenous Target to Preserve Motor Function and Cell Loss after Focal Brain Ischemia in MiceCurrent perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic strokeManagement of ischaemic stroke in the acute setting: review of the current status.Beyond the time window of intravenous thrombolysis: standing by or by stenting?Safety and Efficacy of Solitaire Stent Thrombectomy: Individual Patient Data Meta-Analysis of Randomized Trials.Thrombolysis ImPlementation in Stroke (TIPS): evaluating the effectiveness of a strategy to increase the adoption of best evidence practice--protocol for a cluster randomised controlled trial in acute stroke care.Targeting resolution of neuroinflammation after ischemic stroke with a lipoxin A4 analog: Protective mechanisms and long-term effects on neurological recovery.Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science.Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases.Graphic reanalysis of the two NINDS-tPA trials confirms substantial treatment benefitTrends in thrombolytic use for ischemic stroke in the United States.Pharmacological and non-pharmacological recanalization strategies in acute ischemic stroke.Associations of chronic heart failure with outcome in acute ischaemic stroke patients who received systemic thrombolysis: analysis from VISTA.Thrombolytic therapy for acute ischemic stroke beyond three hours.An in vitro porcine model evaluating a novel stent retriever for thrombectomy of the common carotid artery.Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial.Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment.Endothelial cells and astrocytes: a concerto en duo in ischemic pathophysiology.Mechanical Thrombectomy-Ready Comprehensive Stroke Center Requirements and Endovascular Stroke Systems of Care: Recommendations from the Endovascular Stroke Standards Committee of the Society of Vascular and Interventional Neurology (SVIN).Impact of Protocol Deviations in Acute Ischemic Stroke Treated With Intravenous rt-PA Within 4.5 Hours After Symptom OnsetTime to endovascular reperfusion and degree of disability in acute stroke.siRNA Treatment: "A Sword-in-the-Stone" for Acute Brain InjuriesAcute ischemic stroke update.Endovascular therapy of acute ischemic stroke.Making a case for acute ischemic stroke.Ischaemic stroke: a thrombo-inflammatory disease?Improving reperfusion therapy for acute ischaemic stroke.The emerging agenda of stratified medicine in neurology.Endovascular reperfusion therapies for acute ischemic stroke: dissecting the evidence.Facing the Time Window in Acute Ischemic Stroke: The Infarct Core.Does mechanical thrombectomy in acute embolic stroke have long-term side effects on intracranial vessels? An angiographic follow-up study.Implementation of stroke teams and simulation training shortened process times in a regional stroke network-A network-wide prospective trial.Intravenous thrombolysis for acute ischemic stroke associated to extracranial internal carotid artery occlusion: the ICARO-2 study.Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy.
P2860
Q24194788-1968EF8F-9B6D-4B60-8E75-3DF4B6BE0F79Q24622393-5488894D-A92D-4EF8-BB69-CBF66EC2E0D2Q26750614-BAE37AE5-2C62-42E2-9DDD-37CA6E253648Q26796477-10AFCE78-8584-4CEA-99E3-651C544C33D9Q28595484-86DC9A1F-F713-4BF6-8FFF-9A950C5D3111Q30414441-1A1BE673-9A88-489E-B072-08D2F9B383D5Q30431467-54CBE001-5776-4675-88EE-4D8C1BABBA17Q30431536-EECED2A5-FA2A-4708-B6DB-C0C774D4408FQ31047368-29BF35E2-D77D-48EE-8F8A-4D30F9C24A85Q33593063-337BFB36-42E6-40AA-8892-B620AE2EAEC4Q33695357-008B7230-FDA0-47B1-A855-6E94C4FF0B73Q33734891-16813A87-F629-4851-84DE-9C795ADC390CQ34092740-238ADCBB-8B33-4036-96E0-F61EE3E13268Q34170539-9561BA2B-28FE-4986-8B39-C8F2E9118C34Q34508464-1D31F6FC-3B2D-444D-A6E2-034D29363DE3Q35017281-85B6D341-EF42-4A31-B7CB-B02BE86AC1F4Q35393632-CDC0375E-CE4E-4F2F-8C88-5BB9C98C9104Q35552867-CB03D5F7-4133-46A8-A2B4-95CA4829765BQ35826498-8DC50C16-1169-4036-A21C-174936913057Q35992243-41F3044E-7BFD-4F26-A287-BD21CD249570Q36048610-2C04F7CF-4163-4B10-B4D2-7060CDE0334DQ36072867-3DA7DE26-BC6E-4828-BAF7-EDB693D15512Q36755675-676AF108-00E6-4547-8FE2-BE9B76520491Q37052689-429EFB08-AE71-477F-94F1-CDBCC9C0308BQ37114020-4D10E99F-63EE-4259-AB1D-39F20135DCA3Q37585010-3BB418D8-98EE-4796-AFA1-14349B57E100Q37735842-21DEE5E7-1325-442D-B767-13680F9D9D21Q37835842-A1F8EF21-942D-464F-8088-04F17CE5D436Q37867295-192CEFFF-8FB6-463E-A9E6-6D1ED589326FQ37902388-290C81CE-CEC7-4F69-B21C-F7607E7C9CB3Q37903959-5FAEECDE-0314-48B5-B8D0-D5922EDDE7D8Q38169977-BADA2F95-69D1-4A94-8AF0-52B5C73270A8Q38779165-2AEA6595-6FBF-411B-89EC-032DA603605EQ40022509-1A7B39DF-8C8B-4FAC-987A-F85026C24EF2Q40070329-D661A541-6483-459B-B484-9C9F65098E5CQ47097232-DDB053B0-8469-4436-B05D-782FB52AC7D2Q48268977-FC38943D-52A1-495F-9931-33411F560E85Q51794100-258E74AD-00A4-4B9D-94B9-F21F5BF9B777
P2860
Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Number needed to treat to bene ...... analysis of the ECASS 3 trial
@en
Number needed to treat to bene ...... analysis of the ECASS 3 trial.
@nl
type
label
Number needed to treat to bene ...... analysis of the ECASS 3 trial
@en
Number needed to treat to bene ...... analysis of the ECASS 3 trial.
@nl
prefLabel
Number needed to treat to bene ...... analysis of the ECASS 3 trial
@en
Number needed to treat to bene ...... analysis of the ECASS 3 trial.
@nl
P2093
P2860
P1433
P1476
Number needed to treat to bene ...... analysis of the ECASS 3 trial
@en
P2093
David Liebeskind
Helmi Lutsep
James Grotta
Jeffrey Gornbein
Jeffrey L Saver
Lee Schwamm
Phillip Scott
Sidney Starkman
P2860
P304
P356
10.1161/STROKEAHA.108.543561
P407
P577
2009-06-04T00:00:00Z